Relmada Therapeutics Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Relmada Therapeutics Inc's ROA in the second quarter of 2026?
Relmada Therapeutics Inc recorded a cumulative net loss of $-4 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -2.49%.

However, within the Healthcare sector 241 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3168, from total ROA ranking in the first quarter of 2026 at 3707.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	696.03 %	413.69 %	290.4 %	-62.11 %	-67.21 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-4	-9	-4	-64	-75
Return On Assets (TTM)	-2.49 %	-7.15 %	-5.55 %	-169.18 %	-163.17 %
RLMD's Total Ranking	# 3168	# 3707	# 4556	# 4630	# 4693
Total Assets (TTM) in million	220	235	217	21	28
Seq. Total Assets Change	-6.38 %	8.23 %	929.85 %	-23.71 %	-39.59 %
Seq. Net Income Change	-	-	-	-	-

RLMD's 5 Years Annual ROA >> Back to RLMD Management Effectiveness >> Compare RLMD ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 80
Sector	# 242
Overall	# 2824

Return On Assets Statistics
High	Average	Low
73.33 %	-110.49 %	-645.3 %
(Sep 30 2015)		(Mar 31 2019)

Financial Statements
Relmada Therapeutics Inc's Assets	$ 220 million	RLMD's Balance sheet
Relmada Therapeutics Inc's Income	$ -13 million	Quarterly RLMD's Income Statement
RLMD's Income by Division		See RLMD's Income by Division

Annual Return On Assets	(Sep 30 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-67.53 %	-86.21 %	117.33 %	-31.53 %	88.96 %
Total Assets in million	15	46	332	153	223
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-10	-80	0	-157	-126
Annual Return On Assets	-67.84 %	-174.56 %	0 %	-102.71 %	-56.31 %

RLMD's 5 Years Annual ROA >> Back to RLMD Management Effectiveness >> Compare RLMD ROA to its Competitors

More Return On Assets Ratios
RLMD's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RLMD's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RLMD's Competitors
Subscribers only: Roa for Relmada Therapeutics Inc's Suppliers
Subscribers only: Return On Assets for RLMD's Customers

You may also want to know
RLMD's Roi	RLMD's Inventory Turnover Ratio	RLMD's Growth Rates	RLMD's Dividend Comparisons
	RLMD's Profitability Ratios	RLMD's Asset Turnover Ratio	RLMD's Dividend Growth
RLMD's Roe	RLMD's Valuation Ratios	RLMD's Financial Strength Ratios	RLMD's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:27:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.